Affiliation:
1. V.A. Nasonova Research Institute of Rheumatology
2. V.A. Nasonova Research Institute of Rheumatology;
Far Eastern State Medical University
3. Endocrinology Research Center
Abstract
Glucagon-like peptide-1 receptor agonists (ArGLP-1) are effective drugs for the treatment of type 2 diabetes mellitus and obesity. Recent studies in patients with a wide range of immunoinflammatory diseases suggest important pleiotropic mechanisms of action of these drugs, primarily related to the suppression of inflammation. The article presents new data indicating the prospects for the use of ArGLP-1 in immunoinflammatory rheumatic diseases, which dictates the need for clinical studies. GLP-1 receptor agonists are effective drugs for the treatment of type 2 diabetes mellitus and obesity. Recent studies in patients with a wide range of immune-mediated diseases suggest important pleiotropic mechanisms of action of these drugs, primarily related to the suppression of inflammation. The article presents new data indicating the prospects for the use of ArGLP-1 in immune-mediated rheumatic diseases, which dictates the need for clinical studies.
Reference156 articles.
1. World Health Organization. Obesity: Preventing and managing the global epidemic: Report of a WHO consultation. World Health Organization; 2000.
2. Hruby A, Manson JE, Qi L, Malik VS, Rimm EB, Sun Q, et al. Determinants and consequences of obesity. Am J Public Health. 2016;106(9):1656-1662. doi: 10.2105/AJPH.2016.303326.7
3. Lobstein T, Jackson-Leach R, Powis J, Brinsden H, Gray M. World obesity atlas. 2023. URL: https://www.worldobesity.org/resources/resource-library/world-obesity-atlas-2023
4. Wang Y, Beydoun MA, Min J, Xue H, Kaminsky LA, Cheskin LJ. Has the prevalence of overweight, obesity and central obesity levelled off in the United States? Trends, patterns, disparities, and future projections for the obesity epidemic. Int J Epidemiol. 2020;49(3):810-823. doi: 10.1093/ije/dyz273
5. Mogilenko DA, Sergushichev A, Artyomov MN. Systems immunology approaches to metabolism. Annu Rev Immunol. 2023;41:317-342. doi: 10.1146/annurev-immunol-101220-031513